From the Journals

Survival worse with alcohol-related HCC, compared with other types


 

FROM CANCER


Among patients in the alcohol-related HCC group, median overall survival adjusted for lead-time was 5.8 months for patients who had been abstinent for a median of 1 year, compared with 5.0 months for the nonabstinent patients, a difference that was not statistically significant.

In multivariate analysis, factors significantly associated with worse overall survival included advanced HCC at diagnosis (diffuse or metastatic HCC and/or macrovascular invasion), alkaline phosphatase score, alpha-fetoprotein levels, creatinine, performance status, Child-Pugh score, age plus alcohol-related disease, and male sex plus alcohol-related disease. However, alcohol-related versus non–alcohol-related HCC was no longer statistically significant in multivariate analysis.

They noted that for 199 patients who were diagnosed with HCC as part of a cirrhosis follow-up program, the median overall survival adjusted for lead-time was 11.7 months, compared with 5.4 months for patients whose HCC was detected incidentally (P less than .0001).

The investigators noted that other studies have shown that screening rates for HCC are lower in alcohol abusers and that the most common reason for a lack of screening was failure of clinician to order surveillance in patients with known cirrhosis. In addition, alcoholic patients are less likely to be compliant with screening.

Recommended Reading

VIDEO: Model supports endoscopic resection for some T1b esophageal adenocarcinomas
MDedge Hematology and Oncology
NASH rapidly overtaking hepatitis C as cause of liver cancer
MDedge Hematology and Oncology
New treatment options emerge for intermediate, advanced HCC
MDedge Hematology and Oncology
Colorectal cancer risk stratification enhanced by combining family history and genetic risk scores
MDedge Hematology and Oncology
MDedge Daily News: Why the barber’s chair can help hypertension
MDedge Hematology and Oncology
TACE plus radiotherapy improves outcomes in poor-prognosis hepatocellular carcinoma
MDedge Hematology and Oncology
H. pylori eradication cuts new gastric cancers by half
MDedge Hematology and Oncology
MDedge Daily News: Avoid warfarin’s polypharmacy perils
MDedge Hematology and Oncology
MDedge Daily News: Treating H. pylori slashed new gastric cancers
MDedge Hematology and Oncology
MDedge Daily News: Is kratom the answer to the opioid crisis?
MDedge Hematology and Oncology